EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice

Tamara Božina iD, Livija Šimičević iD, Lana Ganoci iD, Mila Lovrić, Iva Klarica Domjanović, Vladimir Trkulja iD, Nada Božina

Toxics · 15.04.2026 · 14 (4) · 327

DOI: 10.3390/toxics14040327 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxics, online erschienen am 15.04.2026. Verfasst von Tamara Božina und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department for Chemistry and Biochemistry, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 257 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Croatian Science Foundation. Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction (PGx-CardioDrug), Croatian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ATP-binding cassette subfamily G member 2 (ABCG2), also known as breast cancer resistance protein (BCRP), is an efflux transporter expressed in key pharmacokinetic tissues and biological barriers. It regulates exposure to many endogenous compounds, drugs, and environmental toxins. Genetic variability in ABCG2 has been recognised as an important contributor to interindividual variability in drug response, especially in terms of efficacy and toxicity. This narrative review summarises current knowledge on the clinical relevance of ABCG2 genetic variants, with a focus on their effects on pharmacokinetics, adverse drug reactions and drug–drug–gene interactions, as well as their potential implementation in personalised therapy. A literature search was performed in PubMed, Scopus and the Clinical Pharmacogenomics Database (ClinPGx), with an emphasis on clinically relevant studies and available pharmacogenomic guidelines. The most investigated ABCG2 variant, c.421C>A (rs2231142; p.Gln141Lys), is consistently associated with reduced transporter activity and increased systemic exposure to several substrate drugs, including statins, allopurinol and anticancer agents, which may influence both treatment response and the risk of toxicity. Although growing evidence supports the clinical relevance of ABCG2 genotyping, its routine implementation remains limited. Integration of ABCG2 variability into polygenic models and clinical decision-support tools may further improve individualised treatment, particularly in patients with multimorbidity and polypharmacy.

Schlagwörter

Stichwörter der Autor:innen

ABCG2 proteinATP-binding cassette transportersdrug interactionsdrug transportersdrug-related side effects and adverse reactionspharmacogeneticspolygenic risk scoreprecision medicine

Autor:innen und Institutionen

  • Department for Chemistry and Biochemistry, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia.
  • Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia.
  • Department of Basic and Clinical Pharmacology, University of Zagreb School of Medicine, Šalata 3, 10000 Zagreb, Croatia.
  • Division for Laboratory Pharmacology and Toxicology, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Kišpatićeva 12, 10000 Zagreb, Croatia.
  • Croatian Agency for Medicinal Products and Medical Devices, Ksaverska Cesta 4, 10000 Zagreb, Croatia.

ORCID-Profile: Tamara Božina, Livija Šimičević, Lana Ganoci, Vladimir Trkulja

Förderung

  • Croatian Science Foundation. Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction (PGx-CardioDrug)
  • Croatian Science Foundation

Zitieren

APA

Božina, T., Šimičević, L., Ganoci, L., Lovrić, M., Klarica Domjanović, I., Trkulja, V., & Božina, N. (2026). ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice. Toxics, 14(4), 327. https://doi.org/10.3390/toxics14040327

Vancouver

Božina T, Šimičević L, Ganoci L, Lovrić M, Klarica Domjanović I, Trkulja V, et al. ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice. Toxics. 2026;14(4):327. doi:10.3390/toxics14040327

BibTeX
@article{Boina2026,
  author = {Božina, Tamara and Šimičević, Livija and Ganoci, Lana and Lovrić, Mila and Klarica Domjanović, Iva and Trkulja, Vladimir and Božina, Nada},
  title = {ABCG2 Genetic Variability in Drug Exposure and Toxicity: Implications for Clinical Practice},
  journal = {Toxics},
  year = {2026},
  volume = {14},
  number = {4},
  pages = {327},
  doi = {10.3390/toxics14040327}
}
Kostenlos starten →